Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth I Buchbinder

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Cancer Journal (Sudbury, Mass.)|January 24, 2023
Impact of Precision Medicine in Oncology: Immuno-oncologyElizabeth I Buchbinder, F Stephen Hodi
Hematology/Oncology Clinics of North America|June 2, 2014
Interferon, interleukin-2, and other cytokinesElizabeth I Buchbinder, David F McDermott
Investigational New Drugs|April 25, 2023
A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibitionElizabeth I Buchbinder, Anita Giobbie-Hurder, Patrick A Ott
Frontiers in Oncology|October 7, 2015
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical DataPatrick A Ott, F Stephen Hodi, Elizabeth I Buchbinder
Cancers|February 10, 2024
Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for CancerMichael Dougan, Long H Nguyen, Elizabeth I Buchbinder, et al.
Investigational New Drugs|May 29, 2023
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with MelanomaElizabeth I Buchbinder, Anita Giobbie-Hurder, Rizwan Haq, et al.
Clinical Chemistry|May 19, 2017
The Phoenix Rises: The Rebirth of Cancer ImmunotherapyIvan M Blasutig, Sofia Farkona, Elizabeth I Buchbinder, et al.
Journal of the American Academy of Dermatology|July 12, 2021
Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: A retrospective cohort studyAi-Tram N Bui, Amina Bougrine, Elizabeth I Buchbinder, et al.
Journal of Neuro-Oncology|May 21, 2017
Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challengeDaniel N Cagney, Brian M Alexander, F Stephen Hodi, et al.
Journal of Neuro-Oncology|July 13, 2016
Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challengeDaniel N Cagney, Brian M Alexander, F Stephen Hodi, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Cancer Journal (Sudbury, Mass.)|January 24, 2023
Impact of Precision Medicine in Oncology: Immuno-oncologyElizabeth I Buchbinder, F Stephen Hodi
Hematology/Oncology Clinics of North America|June 2, 2014
Interferon, interleukin-2, and other cytokinesElizabeth I Buchbinder, David F McDermott
Investigational New Drugs|April 25, 2023
A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibitionElizabeth I Buchbinder, Anita Giobbie-Hurder, Patrick A Ott
Frontiers in Oncology|October 7, 2015
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical DataPatrick A Ott, F Stephen Hodi, Elizabeth I Buchbinder
Cancers|February 10, 2024
Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for CancerMichael Dougan, Long H Nguyen, Elizabeth I Buchbinder, et al.
Investigational New Drugs|May 29, 2023
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with MelanomaElizabeth I Buchbinder, Anita Giobbie-Hurder, Rizwan Haq, et al.
Clinical Chemistry|May 19, 2017
The Phoenix Rises: The Rebirth of Cancer ImmunotherapyIvan M Blasutig, Sofia Farkona, Elizabeth I Buchbinder, et al.
Journal of the American Academy of Dermatology|July 12, 2021
Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: A retrospective cohort studyAi-Tram N Bui, Amina Bougrine, Elizabeth I Buchbinder, et al.
Journal of Neuro-Oncology|May 21, 2017
Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challengeDaniel N Cagney, Brian M Alexander, F Stephen Hodi, et al.
Journal of Neuro-Oncology|July 13, 2016
Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challengeDaniel N Cagney, Brian M Alexander, F Stephen Hodi, et al.
Pageof 9